23-valent pneumococcal polysaccharide vaccine
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03449459 | Dec 2018 → Dec 2020 | chronic obstructive pulmonary disease | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03802994 | Nov 2018 → Feb 2020 | — | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT05815264 | Sep 2020 → Apr 2021 | pneumonia | Ab&B Bio-tech Co., Ltd.JS | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06703203 | Jul → Aug 2025 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT00142389 | Aug 2004 → Dec 2006 | pneumococcal infection | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02097849 | Feb 2015 → May 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | Missed primary |
| Phase 2 | NCT00282308 | Jan 2006 → Jan 2008 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT06044077 | Sep 2023 → Mar 2024 overdue | pneumococcal infection | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06314867 | Jan 2023 → Dec 2024 overdue | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04278248 | Jan → Jun 2018 | streptococcal pneumonia | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00574548 | Nov 2007 → Feb 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
| Phase 47 trials · 2 met primary | ||||||
| Phase 4 | NCT07640841 | Jun 2026 → Jun 2027 expected | — | Jiangsu Province Centers for Disease Control and Prevention | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05731115 | Feb → May 2023 | pneumococcal infection | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 4 | NCT05471531 | Nov 2021 → Mar 2022 | — | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 4 | NCT05499351 | Oct → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04701788 | Mar → Dec 2021 | — | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT04700618 | Mar → Aug 2021 | — | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT01163747 | Sep 2010 → Dec 2011 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00706550 | Oct 2008 → Sep 2011 | HIV infectious disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT02558751 Comparator | Jul 2013 → Jun 2015 | pneumococcal infection | University of Toledo Health Science Campus | Completed | No outcome recorded |
| Phase 1/2 | NCT07600983 Comparator | May → Nov 2026 expected | pneumococcal infection | CanSino Biologics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03313050 Comparator | Oct 2017 → May 2019 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02451969 Comparator | Apr → Jun 2015 | pneumococcal infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01646398 Comparator | Jun → Oct 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01451086 Comparator | Oct 2011 → Jul 2012 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT00427895 Comparator | Feb 2007 → Aug 2011 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT04989465 Comparator | Sep 2021 | pneumococcal infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04953325 Comparator | Jul → Oct 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03762824 Comparator | Jun 2016 → Sep 2018 | Sjogren syndrome, rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus +1 | Region Skane | Completed | No outcome recorded |
| Phase 4 | NCT02062281 Comparator | Nov → Dec 2013 | influenza, pneumococcal infection | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23-valent pneumococcal polysaccharide vaccine | “Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug...” NCT03449459 ↗29“assigned 340 pregnant Bangladeshi mothers to receive either trivalent inactivated influenza vaccine, or 23-valent pneumococcal polysaccharide vaccine during the third trimester.” PMID 23967126 ↗ Aug 2013 “To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years.” PMID 30215583 ↗ Sep 2018 “23-valent Pneumococcal Polysaccharide Vaccine, produced by Chengdu Institute of Biological Products Co., Ltd. One dose, intramuscular.” NCT07640841 ↗ “This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.” NCT04989465 ↗ “Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.” NCT01451086 ↗ “a 23-valent pneumococcal polysaccharide vaccine (PPV23) in 1800 healthy Chinese adults aged 40-65 y” PMID 41165164 ↗ Oct 2025 “the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗ “23-valent pneumococcal polysaccharide vaccine” NCT03313050 ↗ |
| Known as | 23-valent PPV | “* Intervention: investigational 23-valent PPV” NCT02451969 ↗ |
| Known as | 23vPPV | “Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.” NCT02062281 ↗ |
| Known as | 23vPS | “23-valent Pneumococcal Polysaccharide Vaccine (23vPS)” NCT00427895 ↗ |
| Known as | PPSV23 | “initial 13-valent PCV (PCV13) or 23-valent PPSV (PPSV23)” PMID 24606865 ↗ Mar 2014 |
| Known as | PPV23 | “To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years.” PMID 30215583 ↗ Sep 20183“a 23-valent pneumococcal polysaccharide vaccine (PPV23) in 1800 healthy Chinese adults aged 40-65 y” PMID 41165164 ↗ Oct 2025 “the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗ “23-valent pneumococcal polysaccharide vaccine (referred to as PPV23)” NCT07600983 ↗ |
| Known as | PPV23 vaccine | “1 dose ( 0.5ml) of PPV23 vaccine” NCT07600983 ↗ |
| Modality | Vaccine | “23-valent pneumococcal polysaccharide vaccine” PMID 23967126 ↗ Aug 2013 |
| Route | Intramuscular | “patients received an IM injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL)” NCT00282308 ↗ |